Encompass Health (NYSE:EHC) Price Target Raised to $135.00 at KeyCorp

Encompass Health (NYSE:EHC) had its target price increased by KeyCorp from $122.00 to $135.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have an overweight rating on the stock.

EHC has been the topic of several other research reports. Truist Financial reiterated a “buy” rating and set a $135.00 price target (up previously from $116.00) on shares of Encompass Health in a research note on Monday, April 28th. UBS Group boosted their price target on Encompass Health from $117.00 to $130.00 and gave the company a “buy” rating in a research note on Monday, April 28th. Royal Bank of Canada boosted their price target on Encompass Health from $110.00 to $125.00 and gave the company an “outperform” rating in a research note on Monday, April 28th. Wall Street Zen upgraded Encompass Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Barclays upped their target price on Encompass Health from $118.00 to $129.00 and gave the stock an “overweight” rating in a research note on Friday, April 25th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $122.71.

Encompass Health Stock Up 1.7%

Shares of EHC stock opened at $120.98 on Tuesday. Encompass Health has a 1-year low of $82.74 and a 1-year high of $121.96. The stock’s fifty day moving average price is $108.68 and its 200 day moving average price is $101.65. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04. The company has a market cap of $12.19 billion, a price-to-earnings ratio of 27.13, a price-to-earnings-growth ratio of 2.31 and a beta of 0.91.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.18. The business had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The company’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.12 EPS. On average, research analysts expect that Encompass Health will post 4.8 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Tuesday, July 1st will be given a dividend of $0.17 per share. The ex-dividend date is Tuesday, July 1st. This represents a $0.68 dividend on an annualized basis and a yield of 0.56%. Encompass Health’s dividend payout ratio is currently 14.05%.

Insiders Place Their Bets

In other Encompass Health news, CEO Mark J. Tarr sold 118,384 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the completion of the transaction, the chief executive officer now owns 527,070 shares of the company’s stock, valued at $64,054,817.10. This represents a 18.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP John Patrick Darby sold 10,000 shares of the stock in a transaction that occurred on Tuesday, April 29th. The shares were sold at an average price of $114.79, for a total value of $1,147,900.00. Following the transaction, the executive vice president now directly owns 79,710 shares of the company’s stock, valued at $9,149,910.90. The trade was a 11.15% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 132,663 shares of company stock worth $16,034,082. 2.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Encompass Health

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Acadian Asset Management LLC acquired a new stake in shares of Encompass Health in the first quarter valued at approximately $3,557,000. Geneos Wealth Management Inc. boosted its position in shares of Encompass Health by 159.7% during the first quarter. Geneos Wealth Management Inc. now owns 831 shares of the company’s stock worth $84,000 after buying an additional 511 shares during the period. Intech Investment Management LLC boosted its position in shares of Encompass Health by 21.8% during the first quarter. Intech Investment Management LLC now owns 21,329 shares of the company’s stock worth $2,160,000 after buying an additional 3,815 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Encompass Health by 6.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 390,494 shares of the company’s stock worth $39,549,000 after buying an additional 22,896 shares during the period. Finally, Dean Capital Management boosted its position in shares of Encompass Health by 2.2% during the first quarter. Dean Capital Management now owns 22,680 shares of the company’s stock worth $2,297,000 after buying an additional 483 shares during the period. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.